• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

DNDi Receives Goodwin Award for Its Social Entrepeneurial Approach for the Most Neglected

Siena, Italy / Geneva, Switzerland — 8 May 2008
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

The University of Siena today awarded the Drugs for Neglected Diseases initiative (DNDi) with a Goodwin Award for its innovative needs-driven approach in making 2 new antimalarials available as public goods, and in engaging public and private partners worldwide, especially in neglected disease-endemic countries, to ensure that the best science is made available for those neglected patients.

The Goodwin Award, which is the first one of its kind, is given to entities that – through concrete actions and initiatives – have shown attention to the theme of well-being, and also takes an entrepreneurial approach into perspective. DNDi is one of 4 recipients of the Goodwin Award, which marks the 40th anniversary of the Richard Goodwin Faculty of Economics of the University of Siena.

“We at DNDi are honored to receive this reward as it showcases the progress which DNDi has made since its short life, thanks to our diverse set of partners,” remarked Dr. Bernard Pecoul, Executive Director of DNDi. “We look forward to building upon our current successes by creating new partnerships along with further strengthening of current partnerships to address the needs of the most neglected.”

Prof. Joseph Stiglitz, Colombia University, Nobel Laureate, Prof. Angelo Riccaboni, Chair of the Faculty of Economics, University of Siena, and Dr. Bernard Pécoul, DNDi Executive Director, received the Goodwin Award.

In its short life, DNDi has worked hard to develop a new approach to medical R&D innovation and for access to essential medicines, and is today fortunate to have its first two needs-adapted products reach some of the most neglected patients. In so doing, DNDi has also learned a number of lessons from the experience of developing and delivering ASAQ for Africa and ASMQ for Latin America and Southeast Asia. These are critical in catalyzing DNDi to move forward in its goal to deliver new treatments for the most neglected and to build a robust portfolio that will produce safe, easy-to-use, effective, and affordable drugs.

###

For media inquiries
For more information, or to arrange an interview with Dr Bernard Pecoul:
contact Sadia KAENZIG; skaenzig@dndi.org; +41 (0)79 819 9971; or
Ann-Marie SEVCSIK at amsevcsik@dndi.org; +41 (0)79 814 9147.

About DNDi and its Model

Background on Neglected Tropical Diseases
Tropical diseases such as malaria, leishmaniasis, lymphatic filariasis, Chagas disease, human African trypanosomiasis (HAT), dengue fever, and schistomiasis continue to cause significant morbidity and mortality worldwide. These disabling and/or life threatening diseases represent an enduring unmet medical need and are collectively called “neglected diseases”. Of the 1,556 new drugs approved between 1975 and 2004, only 21 (1.3%) were specifically developed for tropical diseases and tuberculosis, even though these diseases account for 11.4% of the global disease burden.

Although the R&D landscape has significantly changed for neglected diseases since 2000, there is an urgent need for new, field-adapted drugs to treat visceral leishmaniasis (VL), human African trypanosomiasis (HAT or sleeping sickness), and Chagas disease. A potentially fatal disease, VL is present in 62 countries, with 200 million people at risk and 500,000 new cases each year. Therapeutic options for VL are limited as there are significant drawbacks like route of administration, toxicity, or cost. HAT, a fatal disease if not treated, threatens more than 50 million people in 36 countries and has limited treatment options. For Chagas disease, which infects ~8 million and puts 100 million at risk in Central and South America, drugs are needed to treat both acute and chronic disease, as are safer and more effective drugs adapted to patient needs.

Collaborative Mode of Operation
DNDi follows the virtual research model adopted by other product development partnerships (PDPs), whereby most research is outsourced and actively managed by DNDi personnel. As an integral part of its mission, DNDi utilizes South-South and North-South collaborations in working with R&D partners. While using and supporting existing capacity in countries where the diseases are endemic, DNDi helps to build additional capacity in a sustainable manner through technology transfer in the field of drug R&D for neglected diseases. This includes early-stage access to molecules, pharmaceutical and clinical development, and working closely with control programs through, for example, the Leishmaniasis East Africa Platform (LEAP) and Human African Trypanosomiasis (HAT) platforms.

Regional Networks
DNDi has built regional networks of scientists and clinicians actively involved in the research of new drugs for neglected diseases in Asia, Africa, and Latin America, as well as in the conduct of clinical trials in endemic countries.

Current Portfolio
DNDi has 18 projects in its portfolio as of January 2008: 9 discovery, 3 preclinical, 4 clinical, and 2 post-clinical projects. Discovery projects range from library screening on validated targets, reformulation studies, to therapeutic switching. Three preclinical projects will be ready to enter clinical studies by 2009; and clinical projects are ongoing for VL (combination therapies, regional extension of existing drugs) and for HAT (nifurtimox-eflornithine combination therapy [NECT]).

Delivered Products

Two fixed-dose antimalarial ACTs (FACTs ‘ASAQ’ and ‘ASMQ’) have been developed and registered by DNDi and its FACT Project partners – these public goods are treatments which are easy to use (1-2 tablets a day over a 3-day treatment course) for both children and adults. Over 1 million treatments of ASAQ, the fixed-dose combination (FDC) of artesunate and amodiaquine, have now been distributed by industrial partner, sanofi-aventis; and the treatment is now registered in 21 African countries.

Funding
In order to achieve its objectives of building a robust pipeline and delivering 6-8 new treatments by 2014, DNDi requires a total of EUR €274 million. To date, a number of public institutional and private donors have contributed EUR €74 million to DNDi.

Read, watch, share

Loading...
Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

Lab activities
News
20 Feb 2023

First in-person Dengue Alliance meeting brings together experts from dengue-endemic countries to develop treatments for a growing viral threat

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo